R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Director – Market Access Analytics

Data & AnalyticsConfirmed live in the last 24 hours
Full-timeRedwood City, CA, USA

About the Job

Requirements

  • A bachelor's degree is required in business, economics, statistics, mathematics, data science, public health, life sciences, or a related discipline.
  • At least 8 years of relevant experience in pharmaceutical, biotech, healthcare consulting, or analytics environments, including at least 4 years supporting US market access analytics or closely related payer, reimbursement, pricing, contracting, or patient access decisions.
  • Demonstrated success supporting product launches and commercialization, preferably for oncology, specialty, or physician-administered products and in a pre-launch or rapidly scaling organization.
  • Strong understanding of the US market access landscape, including commercial and government payers, pharmacy and medical benefit dynamics, formulary and medical policy, reimbursement, specialty distribution, provider and GPO dynamics, patient support services, and contracting economics.
  • Hands-on experience with market access data such as payer coverage and policy, longitudinal patient claims, prescription and sales, hub and specialty pharmacy, distribution, rebate and contract performance, and account hierarchy data.
  • Expertise in analytical problem solving, including KPI design, segmentation, opportunity assessment, scenario modeling, performance measurement, and translating ambiguous business questions into rigorous analytical approaches.
  • Proficiency with business intelligence and analytical tools such as Tableau or Power BI and advanced Excel and PowerPoint.
  • Ability to present concise, executive-ready narratives and drive decisions across senior and cross-functional stakeholders.
  • Ability to lead through influence, manage multiple external vendors and workstreams, mentor colleagues, and deliver high-quality results within budget and established timelines.
  • Strong business acumen and comfort operating hands-on amid ambiguity in a smaller, rapidly growing company.
  • Ability to travel as needed.

Responsibilities

  • Serve as the Market Access Analytics lead on the US A&I team, developing and executing an integrated analytics plan supporting access strategy, launch readiness, performance monitoring, and business planning across the US portfolio.
  • Act as a strategic thought partner to Market Access leadership and partners in Pricing & Contracting, Payer and Provider Account Management, Field Reimbursement, Patient Services, Trade and Distribution, Brand, Finance, HEOR, and Commercial Analytics.
  • Own and evolve the market access KPI framework, establishing consistent definitions and executive-ready reporting across payer coverage and restrictions, contracting, channel performance, patient access and affordability, and field execution.
  • Lead payer, formulary, and coverage analytics across commercial and government segments, including medical and pharmacy benefit dynamics, covered lives, utilization management, payer policy trends, account segmentation, and access opportunity assessments.
  • Evaluate patient access and reimbursement performance by integrating patient-level claims, hub, specialty pharmacy, distribution, copay, and other relevant data to identify friction points, abandonment drivers, time-to-therapy trends, and opportunities to improve the patient journey.
  • Support contracting decisions through analog assessments, post-contract performance measurement, pull-through analytics, and assessment of the financial and access implications of strategic options. Partner with Finance on gross-to-net assumptions and variance analyses; the role does not own forecasting or gross-to-net calculations.
  • Develop and lead launch and in-market analytical capabilities, including payer archetyping and segmentation, access scenarios, account opportunity assessments, launch dashboards, early performance indicators, and post-launch diagnostic analyses.
  • Integrate primary payer research, secondary data, competitive intelligence, policy and market developments, and HEOR evidence to create a holistic view of access drivers, risks, and opportunities.
  • Partner with Market Access, Information Systems, and Data teams to inform data strategy and acquisition, business requirements, data quality standards, governance, and scalable reporting architecture while complying with applicable regulatory, security, and privacy requirements.
  • Translate complex analyses into recommendations and communicate their strength, limitations, implications, and recommended actions to senior leadership and cross-functional stakeholders.
  • Drive adoption of fit-for-purpose advanced analytics and automation, including scenario modeling, predictive approaches, artificial intelligence, and emerging data sources where they can materially improve access decisions and execution.
  • Hire and manage multiple direct reports.
  • Manage external analytics partners and operating budgets from scoping and vendor selection through quality review and delivery, ensuring rigor, timeliness, knowledge transfer, and value for investment.
  • Help build and scale the function by establishing best practices, mentoring colleagues, and contributing to future team design and talent development as business needs expand.
  • Perform other duties as assigned.

Desired Qualifications

  • An advanced degree (MBA, MPH, MS, PharmD, PhD, or equivalent) is preferred.
  • Oncology and launch experience are strongly preferred.
  • At least 10 years of experience in patient-based forecasting with a focus in Oncology.
  • Experience with targeted oncolytics.
  • Experience collaborating with cross-functional teams.
  • Demonstrated ability to synthesize complex information and influence decision-making at the executive level.
  • Working knowledge of SQL and/or other analytical programming tools.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs